RespiratoryRecon

She doesn't forget her inhaler because she doesn't care. She forgets because her life runs on feeds now, not bathroom schedules.

Anchoring her dose to nursing her baby instead of brushing her teeth sounds like a small concession. Research in chronic lung disease says it's actually a transfer of ownership — from the clinic's protocol to the patient's real life. That's where sustained adherence lives. A discharge script and a manufacturer leaflet don't get her there. A five-minute behavior design conversation before she leaves might.

Do you have that conversation routinely — or does it still feel like improvisation?

Visit Respiratory Recon in the bio for full story and more

Four words have ended more careers than any performance review: "Do more with less."

I've sat on both sides of that table — as an RT manager and as a hospital administrator. The fights are winnable, but only when someone in the room speaks quality outcomes and value-based care. Most of the time, nobody does.

92,000 retirements projected by 2030. Burnout running at 70–79%. Training programs that filled only 62% of available seats last year. This isn't a workforce shortage — it's a structural collapse, and we're the ones building it.

What would it take to change the conversation in your hospital?


http://tiny.cc/RTWorkforce

More than half of people with COPD keep flaring up even on their best inhaler regimen — what if the missing piece isn't another device, but a different signal in the body entirely?

New trial results on a therapy targeting interleukin-33, a molecule involved early in lung inflammation, cut flare-ups regardless of a patient's eosinophil count — the marker most current biologics depend on. That consistency is the real story: it could open add-on treatment to people who've never qualified for it before.

Have you or someone you love hit that wall where the inhalers just stop being enough?


http://tiny.cc/COPDBIOs

Digital COPD Inhaler Training Cuts Errors

If we know most COPD patients are using their inhalers incorrectly, why are we still relying on spirometry and a quick demo instead of digital training that actually fixes the problem?

Digital training for COPD inhaler use can substantially reduce inhaler errors and help clinicians better match patients to the right device. A recent article in AMJ Respiratory reports on a study using a digital therapy comprehensive management platform to evaluate inspiratory capacity and inhaler technique in 64 patients with COPD, alongside 60 newly diagnosed patients who required pressurized metered dose inhalers.

For DPIs, initial error rates were 50%, falling to 16.67% after platform-based training, with the most common issues being insufficient effective inspiratory time and suboptimal inspiratory flow. For pMDIs, errors dropped from 75% to 10% after training, with major problems including hand–mouth incoordination and inadequate inhalation time. Overall, error rates in the digital therapy group were significantly lower than with self-study or video teaching, supporting structured checklists plus digital assessment to individualize inhaler education.

Key points / take home messages
* Digital COPD inhaler training substantially reduced inhaler technique errors for both dry powder and pMDI devices compared with self-study and video education.
* Peak inspiratory flow related to inhaler resistance and inspiratory muscle strength, but not to standard spirometry, highlighting a frequent mismatch between device choice and actual inspiratory capacity.
* Combining checklist-based technique evaluation with digital assessment enables more personalized inhaler selection and training, targeting common errors like posture, exhalation, timing, and coordination.

Source: Malik A. Digital COPD Training May Reduce Inhaler Errors. AMJ Respiratory, 26 May 2026, summarizing Wang L et al., BMC Pulmonary Medicine 2026.

1 Inhaler, 3 Drugs, 12 & Up

Single-inhaler triple therapy is finally approved for asthma at age 12.

FDA has approved budesonide/glycopyrrolate/formoterol (Breztri Aerosphere) for asthma maintenance in patients twelve and older, making it the first single-inhaler triple therapy carrying an asthma indication for adolescents in the United States.

The decision rested on the phase III KALOS and LOGOS trials, which together enrolled more than 4,300 patients. Compared with budesonide/formoterol alone, the triple combination improved trough FEV1 by 71 to 91 mL at 24 weeks and lowered annualized severe exacerbations by 18 to 20 %. Common adverse events included nasopharyngitis, pneumonia, and headache.

At the bedside, this matters most for the patient who keeps showing up at the clinic on a moderate-to-high dose ICS-LABA and still wakes at night, still rescues at school, still cycles through prednisone bursts. Adding a LAMA in one device, rather than layering tiotropium on top, simplifies adherence and removes one more reason to skip a dose.

The label is not a free pass. Pneumonia risk, oropharyngeal candidiasis, adrenal effects, bone density changes, glaucoma, urinary retention — the full ICS-LABA-LAMA safety conversation now belongs to a twelve-year-old's caregiver. Status asthmaticus remains a hard contraindication.

For the respiratory therapist, expect more triple-therapy education in clinic, more device technique checks, and more questions about whether single-inhaler triple displaces or supplements biologic therapy in the truly severe phenotype. It is not a biologic, and it is not a substitute for one.

KEY TAKEAWAYS
* Simplification matters.
* Modest but real gains, roughly 70 to 90 mL FEV1 improvement and a 20% drop in severe exacerbations
* Not a biologic alternative.



Source: Ingram I. New Maintenance Option Approved for Asthma — Breztri becomes the first single-inhaler triple therapy for patients as young as 12 years. MedPage Today. April 29, 2026.

Thought for the weekend....

When you walked into work on Monday....who is your "Husky"?

http://tiny.cc/WorkHusky

GLP-1s and Asthma: More Than Weight Loss

Using a GLP-1 for obesity or diabetes and seeing fewer asthma flares was not on most clinicians’ bingo cards for 2026.

New data from a Danish nationwide self-controlled cohort of 27,523 adults with asthma and comorbid overweight, obesity, or type 2 diabetes reports a 26 percent reduction in asthma exacerbations after GLP-1 receptor agonist initiation compared with the prior year. This signal was consistent whether the GLP-1 was prescribed for obesity or for diabetes, and across patients with and without allergic rhinitis.

Reliever use dropped by 14 percent, inhaled corticosteroid exposure fell by 23 percent, and pneumonia events decreased by 10 percent over the same period. For a working asthma population, that is fewer bursts of systemic steroids, fewer emergency visits, and potentially a lower cumulative steroid burden over time.

Even though individual BMI and weight-loss data were not available in this registry analysis, the pattern reinforces what is seen clinically: when obesity and metabolic dysfunction improve, dyspnea, rescue use, and exacerbation burden often follow.

At the bedside, this nudges the conversation beyond inhaler technique and step-up therapy alone. For patients with asthma plus obesity or type 2 diabetes who are already candidates for GLP-1 therapy, these data support more deliberate collaboration between respiratory, endocrine, and primary care teams when discussing treatment options and goals.

Key Takeaways
* GLP-1 receptor agonists were associated with a 26% reduction in asthma exacerbations in adults with asthma and obesity or type 2 diabetes.
* Rescue inhaler use, ICS exposure, & pneumonia events all decreased after GLP-1 initiation
* For eligible patients, GLP-1 therapy may offer dual benefits: cardiometabolic risk reduction & meaningful improvement in asthma outcomes



Source: European Association for the Study of Obesity. “GLP-1 weight loss medications linked to significant drop in asthma flares.” News-Medical, May 15, 2026.

Exercise Intensity Is the Prescription We Keep Underdosing

More than 4% vigorous activity cut chronic disease risk by up to 61%.

The conversation in pulmonary rehabilitation has long focused on duration and frequency or how many minutes, how many sessions per week. A study published in the European Heart Journal challenges that framing in a way that should land in every rehabilitation program's design conversation.

Researchers analyzed accelerometer data from 96,408 participants and self-reported activity data from 375,730 more. The question they asked wasn't just how much physical activity prevents disease, but what kind. Specifically, what proportion of that activity is vigorous.

Adjusting for total physical activity volume, participants with more than 4% vigorous physical activity had 29 to 61% lower risk across eight chronic disease outcomes compared with those reporting no vigorous activity. For chronic respiratory disease specifically, intensity accounted for 21.4% of the risk reduction....

More than four times the contribution of volume alone (5.6%)

In pulmonary rehab, we often default to moderate-intensity protocols because they're safer to initiate and easier to tolerate. That's clinically sound for early stages. But this data argues that if our goal is long-term disease risk reduction and not just functional improvement, intensity needs to be part of the prescription conversation, not an afterthought.

For patients who can tolerate it, the question isn't whether to add vigorous intervals. It's when and how.

KEY TAKEAWAYS
* Intensity Drives Reduction.
* Respiratory Disease Is Intensity-Sensitive.
* Personalize the Prescription.



Source: Wei J, et al. Proportion of Vigorous Physical Activity and Chronic Disease Risk. European Heart Journal. Published online March 29, 2026. Summarized in: Pulmonology Advisor. April 13, 2026.

COPD Inhaler Device Type Changes Outcomes — Not Just the Drug

Same active ingredients, different delivery and dry powder pulls ahead by a meaningful margin.

For years, the clinical conversation around COPD inhaler therapy has focused on drug class selection. Researchers at UCLA used a large commercial insurance and Medicare Advantage database to compare outcomes among new LAMA-LABA users prescribed three different inhaler types — dry powder (umeclidinium-vilanterol), metered-dose (glycopyrrolate-formoterol), and soft mist (tiotropium-olodaterol). Using propensity score matching, the analysis examined time to first moderate or severe COPD exacerbation.

The results favored the dry powder inhaler. The lead researcher noted this is the second consecutive study showing a dry powder advantage — the first in ICS-LAMA-LABA combinations, now replicated in LAMA-LABA alone. The consistency across two separate patient populations is difficult to dismiss.

Device selection in COPD is not a secondary consideration. For patients at risk for exacerbation, it may be one of the highest-yield decisions we make at the point of prescribing.

Takeaway 1: Among new LAMA-LABA users with COPD, dry powder inhalers were associated with a 14% lower risk for first moderate or severe exacerbation compared with metered-dose inhalers, with a number needed to treat of 17.

Takeaway 2: Soft mist inhalers showed intermediate performance — better than metered-dose but less favorable than dry powder — suggesting a meaningful hierarchy in device effectiveness within the same drug class.

Takeaway 3: Cardiovascular events, UTIs, and pneumonia rates were comparable across all three devices, reinforcing that the exacerbation reduction with dry powder reflects clinical effectiveness rather than safety differences.

Source: Portela GT, et al. *JAMA Internal Medicine. 2026. Reported via Healio, March 18, 2026.

Inhaler adherence is often poorer than it appears, and the choice of assessment tool can change what clinicians uncover. This short read explores the Morisky-Green test and the TAI, comparing what each one tells us, where each falls short, and whether the extra effort of a more detailed assessment is truly worth it.

Estimated reading time: 2 minutes.

http://tiny.cc/AdherenceScore